About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Biomedical Research Group in Gynaecology is a multidisciplinary team made up of clinical specialists in gynaecology and pathology and basic and translational researchers. Our research is clearly translational. Although we take into account the obvious importance of understanding the mechanism at the cellular and molecular level and try to incorporate it into our research, our research is always focused on having a direct applicability to patients and their clinical benefit. On our way to transferring scientific results to clinical practice, we promote innovation and entrepreneurship.
Our group comprises four main research groups, which are closely connected: The clinical research group devoted mainly to clinical projects in all gynaecological cancers; and three translational research groups dedicated to ovarian cancer; endometrial cancer and endometriosis; diseases of the lower female genital tract.
IP: Eva Colas Ortega Collaborators: Raquel Delgado Gil, Miriam Izquierdo Sans Funding agency: Fundació Institut de Recerca HUVH Funding: 102820.06 Reference: VHIR-PHD-2023-005 Duration: 01/12/2023 - 30/11/2027
IP: Eva Colas Ortega Collaborators: Vicente Bebia Conesa, Silvia Cabrera Diaz, Antonio Gil Moreno, Marta Rebull Santamaria, Ana Luzarraga Aznar, Irene De la Calle Fuentes, Melek Denizli, Lourdes Elena Salazar Huayna Funding agency: Instituto de Salud Carlos III Funding: 278300 Reference: DTS23/00091 Duration: 01/01/2024 - 31/12/2026
IP: Eva Colas Ortega Collaborators: Vicente Bebia Conesa, Carina Masferrer Ferragutcasas, Fco Javier De la Torre Fdez de Vega, Silvia Cabrera Diaz, Ana Luzarraga Aznar, Lourdes Elena Salazar Huayna Funding agency: Instituto de Salud Carlos III Funding: 177500 Reference: PI23/01470 Duration: 01/01/2024 - 31/12/2026
IP: Eva Colas Ortega Collaborators: Antonio Gil Moreno, Irene De la Calle Fuentes Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 201869.5 Reference: CPP2022-009817 Duration: 01/10/2023 - 30/09/2026
PhD student: Eva Coll De la Rubia Director/s: Antonio Gil Moreno, Silvia Cabrera Diaz, Eva Colas Ortega University: Universidad Autònoma de Barcelona Year: 2022
PhD student: Antonio Jesús Esgueva Colmenarejo Director/s: Antonio Gil Moreno, Isabel Teresa Rubio Rodríguez University: Universidad Autònoma de Barcelona Year: 2017
Researchers from the centre took part in international debates on AI in healthcare, spin-offs emerging from research were presented, and several initiatives linked to VHIR received recognition in the field of entrepreneurship.
The grants promote new therapeutic strategies and diagnostic tools in highly complex tumors such as glioblastoma, triple-negative breast cancer, and endometrial cancer.
The Department of Health of the Generalitat de Catalunya grants subsidies for carrying out validation tests on innovative projects in the field of health that are in the early stages of development.
